Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 2, 2007, Pages 285-291

  Roberts, Jason A ^a,b   Boots, Rob ^a,b   Rickard, Claire M ^c   Thomas, Peter ^a   Quinn, Jo ^a   Roberts, Darren M ^a   Richards, Brent ^d   Lipman, Jeffrey ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d GOLD COAST UNIVERSITY HOSPITAL   (Australia)

Author keywords

lactams; Antibiotics; Outcome; Sepsis

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; METICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGE; AGED; ANTIBIOTIC SENSITIVITY; APACHE; ARTICLE; BACTERIAL STRAIN; BOLUS INJECTION; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TERTIARY HEALTH CARE; TREATMENT DURATION; ADOLESCENT; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; APACHE; CEFTRIAXONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; INTENSIVE CARE; MALE; MIDDLE AGED; PILOT PROJECTS; SEPSIS; TREATMENT OUTCOME;

EID: 33947497591     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl478     Document Type: Article

References (35)

1. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101 1644-55.
2. Cunha BA. Antibiotic treatment of sepsis. Med Clin North Am 1995; 79: 551-8.
3. Gamacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31: 2742-51.
4. Harbarth S, Garbino J, Pugin J et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115 529-35.
5. Kollef MH, Sherman G, Ward S et al. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74.
6. MacArthur RD, Miller M, Albertson T et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: Experience from the MONARCS trial. Clin Infect Dis 2004; 38: 284-88.
7. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45: 755-73.
8. Joukhadar C, Frossard M, Mayer BX et al. Impaired target site penetration of β-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001; 29: 385-91.
9. Kieft H, Hoepelman AI, Knupp CA et al. Pharmacokinetics of cefepime in patients with the sepsis syndrome. J Antimicrob Chemother 1993; 32 Suppl B: 117-22.
10. Di Giantomasso D, May CN, Bellomo R. Norepinephrine and vital organ blood flow. Intensive Care Med 2002; 28: 1804-9.
11. Di Giantomasso D, May CN, Bellomo R. Norepinephrine and vital organ blood flow during experimental hyperdynamic sepsis. Intensive Care Med 2003; 29: 1774-81.
12. Di Giantomasso D, Bellomo R, May CN. The haemodynamic and metabolic effects of epinephrine in experimental hyperdynamic septic shock. Intensive Care Med 2005; 31: 454-62.
13. Parrillo JE, Parker MM, Natanson C et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113: 227-42.
14. Georges B, Conil JM, Cougot P et al. Cefepime in critically ill patients: Continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther 2005; 43: 360-9.
15. Burgess DS, Hastings RW, Hardin TC. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther 2000; 22: 66-75.
16. Angus BJ, Smith MD, Suputtamongkol Y et al. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000; 50: 184-91.
17. Mouton JW, Vinks AA, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997; 41: 733-8.
18. Jaruratanasirikul S, Sriwiriyajan S, Ingviya N. Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia. J Pharm Pharmacol 2002; 54 1693-6.
19. Lipman J, Gomersall CD, Gin T et al. Continuous infusion ceftazidime in intensive care: A randomized controlled trial. J Antimicrob Chemother 1999; 43: 309-11.
20. Nicolau DP, McNabb J, Lacy MK et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001; 17: 497-504.
21. Kasiakou SK, Sermaides GJ, Michalopoulos A et al. Continuous versus intermittent intravenous administration of antibiotics: A meta-analysis of randomised controlled trials. Lancet Infect Dis 2005; 5: 581-9.
22. Kasiakou SK, Lawrence KR, Choulis N et al. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: A systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs 2005; 65: 2499-511.
23. Kucers A, McK Bennett N. Ceftriaxone. In: Kucers A, McK Bennett N, eds. The Use of Antibiotics. London: William Heinemann Medical Books, 1987, 510-24.
24. Patel IH, Chen S, Parsonnet M et al. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother 1981; 20: 634-41.
25. Brogden RN, Ward A. Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration. Drugs 1988; 35: 604-45.
26. Joynt GM, Lipman J, Gomersall CD et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001; 47: 421-29.
27. Vincent JL, Moreno R, Takala J et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-10.
28. Knaus WA, Draper EA, Wagner DP et al. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-29.
29. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests - Eighth Edition: Approved standard M2-A8. NCCLS, Wayne, PA, USA, 2003.
30. Georges B, Archambaud M, Saivin S et al. Continuous versus intermittent cefepime infusion in critical care. Preliminary results. Pathol Biol (Paris) 1999; 47: 483-5.
31. Marra AR, Bar K, Bearman GM et al. Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infection due to Pseudomonas aeruginosa. J Infect 2006; 53: 30-5.
32. Laupland KB, Davies HD, Church DL et al. Bloodstream infection-associated sepsis, septic shock in critically ill adults: A population-based study. Infection 2004; 32: 59-64.
33. Gursel G, Demirtas S. Value of APACHE II, SOFA and CPIS Scores in predicting prognosis in patients with ventilator-associated pneumonia. Respiration 2006; 73: 503-8.
34. Lau WK, Mercer D, Itani KM et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006; 50: 3556-61.
35. Hanes SD, Wood GC, Herring V et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000; 179: 436-40.